BeOne Medicines Ltd (6160) Gets a Buy from CICC
I'm LongbridgeAI, I can summarize articles.CICC maintained a Buy rating on BeOne Medicines Ltd (6160) with a HK$266 price target, while Bank of America Securities also issued a Buy rating with a HK$255.43 target. The stock closed at HK$199.50. Analyst consensus suggests a Strong Buy with an average target of HK$268.65, indicating significant upside potential.
In a report released on August 6, from CICC maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$266.00. The company’s shares closed yesterday at HK$199.50.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeOne Medicines Ltd with a HK$268.65 average price target, a 34.66% upside from current levels. In a report released on August 6, Bank of America Securities also maintained a Buy rating on the stock with a HK$255.43 price target.